Brothers Build $22 Billion Fortune on Hope for Covid-19 Vaccine, , on November 13, 2020 at 10:00 am

Financial News
By
On November 13, 2020
In Financial News
Tags:

(Bloomberg) — The stock rally sparked by Pfizer Inc.’s promising Covid-19 vaccine trial results boosted many investors’ fortunes, but none so dramatically as a pair of German brothers.Andreas and Thomas Struengmann have collectively added about $8 billion to their wealth this year thanks to their stake in BioNTech SE, the German firm that’s developing the vaccine with Pfizer. BioNTech’s American depositary receipts surged this week after the U.S. drug giant reported the shot they’re working on prevented 90% of symptomatic infections in tens of thousands of volunteers.At $22 billion, the twins have one of the world’s biggest health-care fortunes, according to the Bloomberg Billionaires Index. The brothers, 70, formed their empire by reinvesting the proceeds of their family’s generic drugs businesses.They “have reshaped their fortune by simply believing in science,” said Paul Westall, co-founder of family office recruitment firm Agreus Group.The Struengmanns didn’t respond to requests for comment.Athos ServiceThe brothers set up their family office, Athos Service, soon after Novartis AG announced in 2005 it was buying their drugmaker, Hexal, along with their stake in affiliate EON Labs for a combined 5.7 billion euros ($6.7 billion).Thomas Struengmann said in a December interview with German newspaper Handelsblatt that the brothers initially promised themselves they wouldn’t invest more than 1 billion euros in the biotech sector because of the risks and requisite patience. They ended up exceeding that cap after seeing glimpses of promise.“You want to see your little plants continue to grow,” he said.Their bet on BioNTech epitomizes their ambition of funding transformational drugs. They helped to give the firm 150 million euros in seed money in 2008 and now own about half of the company. Its stock rally has also boosted the fortune of BioNTech Chief Executive Officer Ugur Sahin to more than $4 billion, according to the Bloomberg index, putting him on the cusp of joining the world’s 500 richest people.The Struengmanns also backed Sahin’s previous venture, Ganymed Pharmaceuticals AG, a cancer-treatment company the Turkish-born scientist founded with now-wife Ozlem Tureci.‘Big Elephants’After taking over family-owned drug company Durachemie from their father Ernst in 1979, the brothers sold it seven years later and used the proceeds to set up Hexal. They started with about two-dozen employees in an apartment building near Munich and grew it into the world’s fourth-largest generic-drug company.“Our strength is speed and flexibility,” Thomas, who has a doctorate in business management, said in a 2004 interview. “While the big elephants are making their decisions, we have already taken action.”BioNTech’s U.S. initial public offering last year capped off a busy decade for the brothers.Since 2010, they’ve co-invested with EQT AB in a hearing-aid business from Siemens AG, sold German lender Suedwestbank AG for more than double what they paid for it in 2004 and snapped up stakes in numerous biotech firms including Immatics NV, which recently merged with Arya Sciences Acquisition Corp.Not all their bets have paid off.Immatics’s share price has fallen about a third since it began trading on the Nasdaq in July, while 4SC AG, a German cancer-drug firm in which the Struengmanns are majority shareholders, is down more than a fifth this year. BioNTech had a rocky start, pricing its IPO below its target range, though its shares have since surged 580%.“For us, it’s not primarily about returns,” Thomas said in the Handelsblatt interview. It’s “above all about generating highly effective medical innovations.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Brothers Build $22 Billion Fortune on Hope for Covid-19 Vaccine(Bloomberg) — The stock rally sparked by Pfizer Inc.’s promising Covid-19 vaccine trial results boosted many investors’ fortunes, but none so dramatically as a pair of German brothers.Andreas and Thomas Struengmann have collectively added about $8 billion to their wealth this year thanks to their stake in BioNTech SE, the German firm that’s developing the vaccine with Pfizer. BioNTech’s American depositary receipts surged this week after the U.S. drug giant reported the shot they’re working on prevented 90% of symptomatic infections in tens of thousands of volunteers.At $22 billion, the twins have one of the world’s biggest health-care fortunes, according to the Bloomberg Billionaires Index. The brothers, 70, formed their empire by reinvesting the proceeds of their family’s generic drugs businesses.They “have reshaped their fortune by simply believing in science,” said Paul Westall, co-founder of family office recruitment firm Agreus Group.The Struengmanns didn’t respond to requests for comment.Athos ServiceThe brothers set up their family office, Athos Service, soon after Novartis AG announced in 2005 it was buying their drugmaker, Hexal, along with their stake in affiliate EON Labs for a combined 5.7 billion euros ($6.7 billion).Thomas Struengmann said in a December interview with German newspaper Handelsblatt that the brothers initially promised themselves they wouldn’t invest more than 1 billion euros in the biotech sector because of the risks and requisite patience. They ended up exceeding that cap after seeing glimpses of promise.“You want to see your little plants continue to grow,” he said.Their bet on BioNTech epitomizes their ambition of funding transformational drugs. They helped to give the firm 150 million euros in seed money in 2008 and now own about half of the company. Its stock rally has also boosted the fortune of BioNTech Chief Executive Officer Ugur Sahin to more than $4 billion, according to the Bloomberg index, putting him on the cusp of joining the world’s 500 richest people.The Struengmanns also backed Sahin’s previous venture, Ganymed Pharmaceuticals AG, a cancer-treatment company the Turkish-born scientist founded with now-wife Ozlem Tureci.‘Big Elephants’After taking over family-owned drug company Durachemie from their father Ernst in 1979, the brothers sold it seven years later and used the proceeds to set up Hexal. They started with about two-dozen employees in an apartment building near Munich and grew it into the world’s fourth-largest generic-drug company.“Our strength is speed and flexibility,” Thomas, who has a doctorate in business management, said in a 2004 interview. “While the big elephants are making their decisions, we have already taken action.”BioNTech’s U.S. initial public offering last year capped off a busy decade for the brothers.Since 2010, they’ve co-invested with EQT AB in a hearing-aid business from Siemens AG, sold German lender Suedwestbank AG for more than double what they paid for it in 2004 and snapped up stakes in numerous biotech firms including Immatics NV, which recently merged with Arya Sciences Acquisition Corp.Not all their bets have paid off.Immatics’s share price has fallen about a third since it began trading on the Nasdaq in July, while 4SC AG, a German cancer-drug firm in which the Struengmanns are majority shareholders, is down more than a fifth this year. BioNTech had a rocky start, pricing its IPO below its target range, though its shares have since surged 580%.“For us, it’s not primarily about returns,” Thomas said in the Handelsblatt interview. It’s “above all about generating highly effective medical innovations.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

+65 3105 1295

Taiwan

Coming Soon!

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Follow Us

Market Coverage